Recent Industry Press

10/14/2010 – Mirna Therapeutics Announces Dr. David Johnson as Scientific Advisor

AUSTIN, Texas–(BUSINESS WIRE)–Mirna Therapeutics, Inc. (“Mirna”) announced today that David Johnson, M.D., F.A.C.P., of UT Southwestern in Dallas, has joined the Company as Scientific Advisor.

Dr. David Johnson recently moved from Vanderbilt University in Nashville, Tennessee, to take the helm as the Donald W. Seldin Distinguished Chair in Internal Medicine, and Chairman of the Department of Internal Medicine at the UT Southwestern Medical School in Dallas, Texas. Dr. Johnson is the recipient of numerous honors and awards and served on the Board of Directors of several key institutions and associations, including the American Society of Clinical Oncology (ASCO), the American Board of Internal Medicine, and the National Comprehensive Cancer Network (NCCN). (read the entire release… )

10/08/2010 – Alnylam Scientists Present New Research on Expanded Delivery of RNAi Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company presented new pre-clinical research today at the 8th International M. Judah Folkman Conference, New Frontiers in Therapeutic Development, held October 8-9, 2010 in Cambridge, Mass, highlighting significant advances in the systemic delivery of RNAi therapeutics. The new research demonstrated effective silencing of target genes in distinct cell types and tissues beyond the liver with systemic delivery of RNAi therapeutics. In particular, novel lipid nanoparticles (LNPs) were designed in collaboration with the laboratory of Daniel Anderson, Ph.D. at the Massachusetts Institute of Technology (MIT) to deliver siRNAs to the vascular endothelium, the cells that line blood vessels throughout the body. RNAi-mediated target gene silencing was observed in endothelial cells across a broad range of tissues, with duration of action lasting for over two months after a single dose. Delivery to the vascular endothelium creates new RNAi therapeutic approaches in disease areas including atherosclerosis, diabetes, inflammation, and cancer. Additional new results were also presented regarding delivery of RNAi therapeutics to immune cells. (read the entire release… )

09/30/2010 – miRagen Therapeutics’ Director of Biology to Give Plenary Lecture at Center for Heart Failure Research Symposium in Oslo, Norway

BOULDER, Colo.–(BUSINESS WIRE)–miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced that its Director of Biology, Eva van Rooij, Ph.D., will give a plenary lecture today at the 8th Annual Center for Heart Failure Research Symposium in Oslo, Norway. Dr. van Rooij’s talk, titled “Oligonucleotide-based modulation of microRNAs to control cardiovascular disease,” will review the basis for the development of a modified short nucleic acid sequence targeting microRNA-208 (antimiR-208) as a strategy for intervention in heart disease and introduce compelling new data supporting its potential as a therapeutic agent. Data to be highlighted include antimiR-208 in hypertensive rodent models of heart failure and preliminary dose ranging and toxicology analysis in non-human primates. (read the entire release… )

Subscribe to the miRNA blog

Thank you for subscribing.

Something went wrong.

Related Posts

Add Comment